Pietrantonio, F <br/><br/>
Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients.  [electronic resource] 

 -  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico  Jul 2013 
 - 582-6 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1699-3055 
<br/><br/><label>Standard No.: </label>10.1007/s12094-012-0971-3  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents--administration & dosage<br/>Camptothecin--administration & dosage<br/>Colorectal Neoplasms--drug therapy<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Immunohistochemistry<br/>Irinotecan<br/>Leucovorin--administration & dosage<br/>Male<br/>Middle Aged<br/>bcl-2-Associated X Protein--metabolism